β-Elemene vinylated coupling derivatives, their preparation and use in the preparation of antitumor drugs
The synthesis of β-elemenvinylated coupling derivatives addresses the solubility and bioavailability issues of β-elemene, resulting in more effective antitumor drugs for treating cancers like lung and liver cancer.
Patent Information
- Application Number
- JP2023550584
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-02-28
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2042-11-17
AI Technical Summary
Existing β-elemene antitumor drugs suffer from low water solubility and bioavailability, limiting their clinical application and requiring structural modifications to enhance their therapeutic efficacy.
Development of β-elemenvinylated coupling derivatives through a synthetic route involving monobromine substitution, selective nucleophilic substitution, and vinylation coupling to improve water solubility and bioavailability.
The β-elemenvinylated coupling derivatives demonstrate enhanced antitumor activity against various cancer types, including lung cancer, liver cancer, and colorectal cancer, with improved solubility and reduced side effects.
Smart Images

Figure 0007578336000001 
Figure 0007578336000002 
Figure 0007578336000003
Abstract
Description
[Technical field]
[0001] This application claims priority based on a Chinese patent application bearing application number CN202210185780.6, filed with the China Patent Office on February 28, 2022, and entitled "β-elemene vinylated coupling derivatives, and their preparation and application in the preparation of antitumor drugs," the entire contents of which are incorporated herein by reference.
[0002] The present invention relates to the technical field of preparing β-elemene derivatives, in particular to β-elemene vinylation coupling derivatives, and their preparation and use in the preparation of antitumor drugs. [Background technology]
[0003] Elemene is a small molecule volatile oil compound, mainly extracted from the tuberous root of Curcuma wenyujin (YHChen et C.Ling). Elemene currently reported in the literature mainly includes α-elemene, (±)-β-elemene, γ-elemene, and δ-elemene, among which (-)-β-elemene is the main active ingredient that exerts antitumor effects, has a wide range of antitumor activity, and has a certain therapeutic effect against various cancers, such as liver cancer, breast cancer, and lung cancer. At present, various preparations with elemene as the main component have obtained a certain anticancer therapeutic effect in clinical trials.
[0004] β-elemene is one of the few new antitumor drugs with independent intellectual property rights in China, and research into its derivatives has made great progress in recent years. From the results of structure-activity relationship research, it is found that the double bond and its skeleton of β-elemene have a significant effect on its activity, and as long as the three double bonds are not destroyed, the activity of the compound is not significantly affected. However, elemene has low polarity and poor water solubility, so that its bioavailability when administered orally is low, limiting its clinical application. Therefore, it is necessary to modify the structure of elemene to obtain an elemene derivative that has good water solubility, higher bioavailability when administered orally, better biological activity than elemene, and fewer side effects.
[0005] Structural modification of β-elemene began in the 1970s and has developed to the present day, with more than 150 types of β-elemene derivatives being synthesized, including several major categories such as reduction-oxidation, sulfur-containing, nitrogen-containing, esters, acids, alcohols, glycosides, etc. Currently, there is very little research related to β-elemene vinylation coupling. Summary of the Invention [Problem to be solved by the invention]
[0006] The first objective of the present invention is to address the shortcomings of the prior art by constructing a series of β-elemene vinylation coupling derivatives using β-elemene as a base, providing β-elemene vinylation coupling derivatives, and studying their antitumor activity, which is expected to lead to the development of new antitumor drugs. [Means for solving the problem]
[0007] The present invention provides a β-elemene vinylation coupling derivative, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharma- ceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof, wherein the structure of the β-elemene vinylation coupling derivative is represented by formula (I): [ka] In formula (I), each R is independently any one selected from the following structural fragments: [ka] Furthermore, the β-elemene vinylation coupling derivative is any one selected from the structures represented by compounds 1 to 22. [ka] The second object of the present invention is to provide a method for preparing said β-elemene vinylated coupling derivatives.
[0008] In the present invention, the preparation of the β-elemene vinylation coupling derivative having the structure represented by formula (I) is carried out in the following synthetic route: [ka] in particular, (1) First, a step of obtaining intermediate (A-2) by a monobromine substitution reaction at the 13th allylic position of β-elemene (A-1); (2) obtaining intermediate (A-3) by selective nucleophilic substitution reaction of intermediate (A-2); (3) Finally, a synthetic route including the step of vinylation coupling of intermediate (A-3) with alkene bromide (A-4) to obtain a β-elemene vinylation coupling derivative having the structure represented by formula (I) is adopted.
[0009] The β-elemene vinylation coupling derivative having the structure represented by formula (I) according to the present invention is prepared by the above-mentioned method, but the conditions of the above-mentioned method, such as reactants, solvents, amounts of compounds used, reaction temperature, reaction time, etc., are not limited to the above description. The compound according to the present invention can also be conveniently prepared by any combination of various synthesis methods described herein or known to those skilled in the art, and such combinations can be easily performed by those skilled in the art.
[0010] Step (1) of each synthetic route according to the present invention can be adopted from the prior art, for example, from Publication No. CN110683932A.
[0011] The third object of the present invention provides the application of said β-elemene vinylated coupling derivatives or their optical isomers, racemates, single enantiomers, possible diastereomers, or pharma- ceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates thereof in the preparation of antitumor drugs.
[0012] The fourth object of the present invention is to provide an antitumor drug containing a safe and effective amount of the above-mentioned β-elemene vinylated coupling derivative, or its optical isomer, racemate, single enantiomer, possible diastereomer, or its pharma- ceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate.
[0013] Preferably, the antitumor drug further comprises a pharma- ceutically acceptable carrier.
[0014] Preferably, in said application and said antitumor drug, said tumor comprises colon cancer, lung cancer.
[0015] Since the compound according to the present invention has activity of inhibiting the proliferation of various tumor cell lines, the compound according to the present invention and various crystal forms thereof, pharma- ceutically acceptable inorganic or organic salts, hydrates or solvates, as well as pharmaceutical compositions containing the compound according to the present invention as a main active ingredient, can be applied to the treatment, prevention, and alleviation of various diseases, including various cancers.
[0016] The pharmaceutical composition according to the present invention contains the compound according to the present invention or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable excipient or carrier within a safe and effective amount. In particular, the "safe and effective amount" refers to an amount of the compound sufficient to clearly improve the condition without causing serious side effects. In general, the pharmaceutical composition contains 1 to 2000 mg of the compound according to the present invention per agent, and more preferably, contains 5 to 1000 mg of the compound according to the present invention per agent. Preferably, the "one agent" is one capsule or tablet.
[0017] "Pharmaceutically acceptable carrier" means one or more compatible solid or liquid fillers or gel-like substances that are suitable for human use and require sufficient purity and sufficiently low toxicity. "Compatible" means that each component in the composition can be doped with the compound of the present invention and between them without significantly reducing the efficacy of the compound. Examples of pharmaceutically acceptable carrier moieties include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyhydric alcohols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers, wetting agents (e.g., sodium dodecyl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0018] The method of administration of the compound or pharmaceutical composition according to the present invention is not particularly limited, but representative administration methods include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
[0019] Solid dosage forms used for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or is mixed with at least one of the following: (a) fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, and the like. (e) solution retarders such as paraffin; (f) absorption enhancers such as quaternary ammonium compounds; (g) wetting agents such as cetyl alcohol, glyceryl monostearate; (h) adsorbents such as kaolin; (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium dodecyl sulfate or mixtures thereof. For capsules, tablets and pills, the dosage form can also contain buffering agents.
[0020] Solid dosage forms such as tablets, sugar-coated tablets, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other materials known in the art. They may also contain opacifying agents, and in such compositions the release of the active compound or compounds may be delayed at a certain location in the digestive tract. Specific examples of embedding components that can be used are polymeric and wax-based materials. If necessary, the active compound may be formed into microcapsules with one or more of the above-mentioned excipients.
[0021] The liquid dosage form used for oral administration includes pharma- ceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.In addition to the active compound, the liquid dosage form can include inert diluents conventionally used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures of these substances.
[0022] In addition to these inert diluents, the compositions can contain adjuvants, such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, and perfumes.
[0023] Suspensions may contain, in addition to the active compounds, suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide, and agar-agar, or mixtures of these substances.
[0024] Compositions for parenteral injection can include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols, and suitable mixtures thereof.
[0025] The dosage forms of the compounds of the present invention used for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient may need to be mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers or propellants as required.
[0026] The compounds of the present invention can be administered alone or in combination with other pharma- ceutically acceptable compounds.
[0027] When using a pharmaceutical composition, a safe and effective amount of the compound according to the present invention is applied to a mammal (e.g., human) in need of treatment, and the dosage at the time of administration is a pharmacologic effective dosage, and for a human weighing 60 kg, the daily dosage is usually 1-5000 mg, preferably 5-2000 mg. Of course, the specific dosage must take into account factors such as the administration route and the health condition of the patient, and these are within the technical scope of a skilled physician.
[0028] Compared with the prior art, the main advantages of the present invention are as follows: The present invention provides β-elemene vinylation coupling derivatives having the structure represented by formula (I), pharmaceutical compositions and hydrates containing β-elemene vinylation coupling derivatives having the structure represented by formula (I), as well as isotopic derivatives, chiral isomers, variants, different salts, prodrugs and formulations of these compounds. The present invention further provides the preparation method and use of said β-elemene vinylation coupling derivatives, and the inhibitory activity of these compounds against the proliferation of various tumor cell lines. The present invention provides a method for the preparation of β-elemene C(sp 3 )-C(sp 2 ) bond coupling derivatives are expected to be candidates for antitumor drugs for treating various cancers, such as lung cancer, liver cancer, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer, breast cancer, or glioma. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] The present invention will be further described below in conjunction with specific examples.It should be understood that these examples are only used to illustrate the present invention, and do not limit the scope of the present invention.In the following examples, the operation methods that do not show specific conditions usually follow conventional conditions or conditions recommended by manufacturers.
[0030] Example 1: Preparation of Compound 1 [ka] Intermediate 1d (1) Compound 1a (20 mmol, 100 mol%) in dichloromethane (DCM, 80 mL) was dissolved in CBr 4 (30 mmol, 150 mol%) was added, and then PPh was added using a constant pressure dropping funnel under nitrogen gas protection. 3 A solution of 1b (60 mmol, 300 mol%) in DCM (70 mL) was slowly added dropwise. The progress of the reaction was monitored by TLC. After the reaction was completed, about half of the dichloromethane was removed under reduced pressure, and then petroleum ether (PE, 100 mL) was added to precipitate triphenylphosphine oxide (TPPO). After filtration through Celite and evaporation, the residue was dissolved in PE (50 mL) to further precipitate TPPO. This was repeated several times to obtain crude dibromide 1b (~20 mmol, 100 mol%), which was used directly in the next step. (2) At room temperature, crude dibromide 1b (~20 mmol, 100 mol%) was reacted with NEt 3 Dimethyl phosphite (60 mmol, 300 mol%) was added to a solution of 1c (60 mmol, 300 mol%) in anhydrous N,N-dimethylformamide (DMF, 20 mL) and stirred overnight. DMF was removed under reduced pressure, aqueous solution (60 mL) was added, extracted with PE (2 x 100 mL), and the combined organic phase was washed with aqueous hydrochloric acid (1 M, 55 mL) and then dried over anhydrous sodium sulfate. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain crude product 1c, which was used directly in the next step. (3) The crude product 1c from the previous step (~20 mmol, 100 mol%) was dissolved in isopropanol (i-PrOH, 30 mL). Solid sodium hydroxide (17 mmol, 85 mol%) was added and heated to reflux for more than 5 h. The reaction mixture was cooled to room temperature and extracted with n-hexane (100 mL). The combined organic phase was washed with aqueous hydrochloric acid (1 M, 75 mL), aqueous hydrochloric acid (2 x 100 mL), and then dried over anhydrous sodium sulfate. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluted with a system of ethyl acetate / petroleum ether (0.5%)) to give a white solid 1d (2.65 g, 62% yield). 1 H NMR (500 MHz, CDCl3 ) δ 7.25-7.21 (m, 2H), 7.04 (d, J = 14.0 Hz, 1H), 6.87-6.83 (m, 2H), 6.61 (d, J = 13.9 Hz, 1H), 3.81 (s, 3H).
[0031] compound 1 In an oven-dried Schlenk tube equipped with a magnetic stirrer, intermediate 1d (0.150 mmol, 1.0 equiv), intermediate 1e (0.300 mmol, 2.0 equiv), and catalyst NiCl were added. 2 (PPh 3 ) 2 (9.8 mg, 0.015 mmol, 10 mol%), reducing agent Zn powder (19.6 mg, 0.300 mmol, 2.0 equiv), coordination compound 4,4'-di-tert-butyl-2,2'-bipyridine (4.0 mg, 0.015 mmol, 10 mol%) and additive MgCl 2 (28.6 mg, 0.300 mmol, 2.0 equiv) were added in sequence. The Schlenk flask was then evacuated three times with a double-column tube so that the reaction system was under a nitrogen atmosphere, and finally, N,N-dimethylacetamide (DMA, 1.0 mL) solution was added by syringe and stirred at 25 °C for 12 h. After the reaction was completed, the reaction mixture was directly purified by silica gel column chromatography (eluted with a system of ethyl acetate / petroleum ether (2%)) without workup to obtain a colorless oily liquid 1 (43.3 mg, 86% yield). 1 H NMR (500 MHz, CDCl 3) δ 7.31 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 6.37 (d, J = 15.8 Hz, 1H), 6.08 (dt, J = 15.7, 7.1 Hz, 1H), 5.83 (dd, J = 17.4, 10.9 Hz, 1H), 4.92 (dd, J = 8.1, 1.2 Hz, 1H), 4.89 (s, 1H), 4.87 (s, 1H), 4.83 (dd, J = 5.0, 1.3 Hz, 2H), 4.61 (s, 1H), 3.81 (s, 3H), 2.95 (d, J = 7.0 Hz, 2H), 2.02 (dd, J = 11.8, 4.3 Hz, 2H), 1.72 (s, 3H), 1.64-1.59 (m, 2H), 1.54-1.42 (m, 4H), 1.02 (s, 3H). 13 C NMR (126 MHz, CDCl 3 ) δ 158.92, 153.40, 150.38, 147.81, 130.81, 130.65, 127.27, 126.63, 114.06, 112.26, 110.01, 108.76, 55.41, 52.90, 44.30, 40.09, 39.98, 38.83, 33.36, 27.33, 24.93, 16.76. HRMS (ESI) m / z ([MH] - ) calcd for C 24 H 31 O: 335.2380. Found: 335.2380.
[0032] Example 2: Preparation of Compound 2
change
[0033] Example 3: Preparation of Compound 3
change
[0034] Example 4: Preparation of compound 4
change
[0035] Example 5: Preparation of Compound 5
change
[0036] Example 6: Preparation of Compound 6 [ka] Intermediate 6g The synthesis steps of intermediate 5g in Example 5 were repeated to obtain colorless oily liquid 6g (267 mg, yield 82%). 1 H NMR (500 MHz, CDCl 3 ) δ 7.98 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 14.0 Hz, 1H), 6.91 (d, J = 14.0 Hz, 1H), 5.09 (t, J = 7.1 Hz, 1H), 4.40-4.29 (m, 2H), 1.99 (dd, J = 22.5, 7.6 Hz, 2H), 1.80 (dt, J = 12.5, 6.3 Hz, 1H), 1.66 (s, 3H), 1.59 (s, 3H), 1.34-1.28 (m, 2H), 1.24 (dd, J = 15.0, 7.7 Hz, 2H), 0.96 (d, J = 6.6 Hz, 3H). compound 6 Following the synthesis steps of compound 1 in Example 1, a colorless oily liquid 6 (63.7 mg, yield 87%) was obtained. 1 H NMR (500 MHz, CDCl 3) δ 7.97 (d、 J = 7.9 Hz、 2H)、 7.41 (d、 J = 8.0 Hz、 2H)、 6.50-6.29 (m、 2H)、 5.82 (dd、 J = 17.4、 10.8 Hz、 1H)、 5.10 (dd、 J = 6.9、 5.9 Hz、 1H)、 4.92 (s、 1H)、 4.91 (s、 1H)、 4.89 (d、 J = 2.6 Hz、 1H)、 4.82 (d、 J = 5.1 Hz、 2H)、 4.60 (s、 1H)、 4.46-4.27 (m、 2H)、 2.99 (d、 J = 6.8 Hz、 2H)、 2.07-1.97 (m、 4H)、 1.92 (d、 J = 10.1 Hz、 1H)、 1.86-1.79 (m、 1H)、 1.75 (d、 J = 9.2 Hz、 1H)、 1.71 (s、 3H)、 1.68 (s、 3H)、 1.61 (s、 3H)、 1.56 (d、 J = 8.1 Hz、 1H)、 1.51-1.44 (m、 3H)、 1.31 (dd、 J = 17.7、 7.5 Hz、 4H)、 1.01 (s、 3H)、 0.97 (d、 J = 6.5 Hz、 3H). 13 C NMR (126 MHz、 CDCl 3 ) δ 166.64、 152.66、 150.27、 147.72、 142.14、 131.72、 131.48、 130.72、 130.00、 129.01 125.99、 124.71、 112.30、 110.08、 109.31、 63.53、 52.87、 44.47、 40.00 (d、 J = 10.8 Hz)、 38.84、 37.13、 35.66、 35.06、 33.35、 29.72、 27.30、 25.84、 25.54、 24.93、 19.65、 17.80、 16.75. HRMS (ESI) m / z ([M+H] + ) calcd for C 34 H 49 O 2 : 489.3727. Found: 489.3730.
[0037] Example 7: Preparation of Compound 7
change
[0038] Example 8: Preparation of compound 8
change
[0039] Example 9: Preparation of Compound 9
change
[0040] Example 10: Preparation of Compound 10 [ka] 10g intermediate The synthesis steps of intermediate 5g in Example 5 were repeated to obtain white solid 10g (1.07 g, yield 91%). 1 H NMR (500 MHz, CDCl 3 ) δ 7.97 (dd, J = 8.5, 1.6 Hz, 2H), 7.39-7.34 (m, 2H), 7.34-7.30 (m, 2H), 7.30-7.27 (m, 2H), 7.20 (dd, J = 8.1, 6.8 Hz, 2H), 7.16-7.10 (m, 4H), 6.91 (d, J = 14.1 Hz, 1H), 6.82-6.76 (m, 2H), 6.62-6.56 (m, 2H), 4.57 (dd, J = 5.5, 3.9 Hz, 2H), 4.16 (dd, J = 5.6, 3.9Hz, 2H), 3.41 (t, J = 7.4 Hz, 2H), 2.92 (t, J = 7.5 Hz, 2H). compound 10 Following the synthesis steps of compound 1 in Example 1, a colorless oily liquid 10 (86.4 mg, yield 81%) was obtained. 1 H NMR (500 MHz, CDCl 3) δ 7.96 (d、 J = 8.2 Hz、 2H)、 7.42-7.36 (m、 4H)、 7.31 (d、 J = 6.2 Hz、 3H)、 7.23-7.19 (m、 2H)、 7.16 (d、 J = 7.2 Hz、 3H)、 6.82 (d、 J = 8.7 Hz、 2H)、 6.61 (d、 J = 8.7 Hz、 2H)、 6.51-6.31 (m、 2H)、 5.86-5.80 (m、 1H)、 5.11 (d、 J = 13.8 Hz、 1H)、 4.92 (s、 1H)、 4.91 (s、 1H)、 4.84 (d、 J = 6.9 Hz、 2H)、 4.61 (s、 1H)、 4.59-4.56 (m、 2H)、 4.20-4.14 (m、 2H)、 3.43 (t、 J = 7.4 Hz、 2H)、 3.00 (d、 J = 8.7 Hz、 2H)、 2.95-2.91 (m、 2H)、 2.05-2.00 (m、 2H)、 1.73 (s、 3H)、 1.62 (dd、 J = 7.5、 3.3 Hz、 2H)、 1.51-1.45 (m、 4H)、 1.03 (s、 3H). 13 C NMR (126 MHz、 CDCl 3 ) δ 166.44、 156.86、 152.58、 150.24、 148.88、 147.68、 142.94、 142.41、 141.75、 141.03、 135.41 (d、 J = 5.3 Hz)、 131.93、 131.86、 130.62、 130.16、 129.63、 129.49、 128.46、 128.34、 127.07、 126.73、 125.98、 113.72、 113.13、 112.29、 110.07、 109.33、 79.52、 65.88、 63.33、 52.83、 44.43、 42.93、 41.65、 39.96 (d、 J = 9.6 Hz)、 38.75 (d、 J = 14.8 Hz)、 33.31、 29.81、 27.26、 24.92. HRMS (ESI) m / z ([M+Na] + ) calcd for C 48 H 51 ClNaO3 : 733.3419. Found: 733.3482.
[0041] Example 11: Tumor cell proliferation inhibition assay In vitro antitumor activity evaluation 1. Experimental equipment and reagents 1.1 Equipment Biological safety cabinet (Shanghai Baiki Biological Technology Co., Ltd.), constant temperature carbon dioxide incubator (THERMO), enzyme immunoassay device (Spark), inverted microscope (Nikon), pipette gun (Eppendorf) and centrifuge (Beckman Coulter). 1.2 Reagents McCoy'S 5A (Zhejiang Senrui Biological Technology Co., Ltd.), RPMI 1640 (Zhejiang Senrui Biological Technology Co., Ltd.), Fatal Bovine Serum (BI), PBS (Zhejiang Senrui Biological Technology Co., Ltd.), Trypsin (Zhejiang Senrui Biological Technology Co., Ltd.), DMSO (Coolaber) and CCK-8 (Coolaber). 1.3 Cell lines Human colon cancer cells (HCT116), human lung cancer cells (A549).
[0042] 2. Experimental Method 1) Test cells in the logarithmic growth phase were harvested, trypsinized, counted, and then diluted to 5 x 10 4 Add 100 µL (5 × 10) per well of a 96-well plate at a concentration of 10 / mL. 3 Cells were seeded at 1000 x 1000 cells / well and incubated at 37°C in 5% CO. 2 The cells were cultured in an incubator for 24 hours. 2) The test drugs were diluted to different concentrations in McCoy's 5A or RPMI 1640 complete medium. In the experimental group, the culture medium containing the test samples at different concentrations was replaced, and in the control group, the culture medium containing the same volume of the solvent (DMSO) was replaced. Three parallel culture wells were set up for each group, and the cells were incubated at 37°C in 5% CO 2 The culture was continued in an incubator for 48 hours. Among them, for HCT116 cells, McCoy's 5A complete medium was used, and for A549 cells, RPMI 1640 complete medium was used. 3) 10 μL of CCK-8 solution was added to each well, and the plates were incubated at 37°C for 1 to 4 hours. The absorbance value (OD value) of each well was measured at 490 nm using a microplate reader. 4) The survival rate and inhibition rate were calculated according to the following formula: Cell viability = [(A s -A b ) / (A c -A b )] × 100% Inhibition rate = [(A c -A s ) / (A c -A b )] × 100% GraphPad Prism 7.0 software was used to plot sigmoidal dose-survival curves using a nonlinear regression model to determine IC 50 The value was calculated. A s : Absorbance of the experimental well (medium containing cells, CCK-8, test drug) A c : Absorbance of control wells (medium containing cells, CCK-8, solvent (DMSO) A b : Absorbance of blank well (medium containing no cells or test drug, CCK-8)
[0043] 3. Experimental Results The inhibitory effects of the target compound and the positive control drug β-elemene on the proliferation of the two tumor cells were measured according to the above-mentioned experimental method, and the results are shown in Table 1. [Table 1] The tumor cells were treated with 100 μM of compound for 48 h. The results showed that the tumor cell proliferation inhibitory effect of compound 4 was significantly stronger than that of the positive control, β-elemene. Compound 4 was selected and the IC 50 The measured values are shown in Table 2. [Table 2] Different concentrations of compounds were applied to the tumor cells for 48 h. The results showed that compound 4 exhibited significantly stronger cell proliferation inhibitory activity than the positive control, β-elemene. Furthermore, it should be understood that, after reading the above description of the present invention, one skilled in the art may make various changes or modifications to the present invention, and that equivalent forms thereof are also included within the scope defined by the appended claims.
Claims
1. A β-elemene vinylation coupling derivative, or an optical isomer, racemate, single enantiomer, diastereomer, or a pharma- ceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof, characterized in that the structure of the β-elemene derivative is represented by formula (I): A β-elemene vinylation coupling derivative, or an optical isomer, racemate, single enantiomer, diastereomer, or a pharma-ceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof. 【Chemistry 1】 (In formula (I), each R is independently any one selected from the following structural fragments.) 【Chemistry 2】
2. The β-elemene vinylation coupling derivative according to claim 1, characterized in that the β-elemene vinylation coupling derivative is any one selected from the structures represented by compounds 1 to 22, or an optical isomer, racemate, single enantiomer, diastereomer, or a pharma- ceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof. 【Chemistry 3】
3. In the following synthetic route, 【Chemistry 4】 In the formula, each R is independently one of the following structural fragments: 【Chemistry 5】 (1) first, a step of obtaining an intermediate (A-2) by a monobromine substitution reaction at the allylic position of β-elemene (A-1); (2) obtaining intermediate (A-3) by selective nucleophilic substitution reaction of intermediate (A-2); (3) Finally, a step of vinylation coupling between intermediate (A-3) and alkene bromide (A-4) to obtain a vinylation coupling derivative having a structure represented by formula (I).
4. Use of the β-elemene vinylated coupling derivative according to claim 1 or 2, or an optical isomer, racemate, single enantiomer, diastereomer, or a pharma- ceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof, in the preparation of an antitumor drug.
5. The use according to claim 4, characterized in that the tumor comprises colon cancer, lung cancer, liver cancer, gastric cancer, prostate cancer, ovarian cancer, breast cancer or glioma.
6. The use according to claim 4, characterized in that the administration methods of the β-elemene vinylated coupling derivative, or its optical isomer, racemate, single enantiomer, possible diastereomer, or its pharma- ceutically acceptable salt, deuterated derivative, hydrate, solvate are oral, intratumoral, rectal, parenteral and topical administration.
7. Solid dosage forms used for oral administration include capsules, tablets, pills, powders, and granules; In the solid dosage form, the β-elemene vinylated coupling derivative, or its optical isomer, racemate, single enantiomer, possible diastereomer, or its pharma- ceutically acceptable salt, deuterated derivative, hydrate, solvate, is mixed with at least one inert excipient or carrier, including sodium citrate, dicalcium phosphate, or is not mixed with any of the following: a filler or solubilizer, a binder, a humectant, a disintegrant, a dissolution retarder, an absorption enhancer, a wetting agent, an adsorbent, a lubricant, including: starch, lactose, sucrose, glucose, mannitol, and silicic acid; and a binder, including hydroxymethylcellulose, alginate, gelatin, polysaccharide, cellulose, cellulose acetate, cellulose acetate, cellulose ester, cellulose phosphate, cellulose ester ...
7. The method according to claim 6, characterized in that the cellulose acetate solution is mixed with the above-mentioned cellulose acetate esters, the cellulose acetate esters being carboxymethylcellulose, ...
8. The use according to claim 4, characterized in that the daily dosage is 1 to 5000 mg for a human weighing 60 kg.
9. An antitumor drug comprising a safe and effective amount of the β-elemene vinylated coupling derivative according to claim 1 or 2, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharma- ceutically acceptable salt, deuterated derivative, hydrate, or solvate thereof.
10. The antitumor drug of claim 9, further comprising a pharma- ceutically acceptable excipient or carrier.
11. The antitumor drug according to claim 9 or 10, characterized in that the tumor comprises colon cancer or lung cancer.
12. The antitumor drug according to claim 9, characterized in that the antitumor drug contains 1 to 2000 mg / agent (wherein one agent is one capsule or tablet) of the β-elemene vinylated coupling derivative, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharma- ceutical acceptable salt, deuterated derivative, hydrate, or solvate thereof.
13. The antitumor drug according to claim 9, characterized in that the pharma- ceutically acceptable carrier is cellulose and its derivatives, gelatin, talc, solid lubricants, calcium sulfate, vegetable oils, polyhydric alcohols, emulsifiers, wetting agents, colorants, flavorings, stabilizers, antioxidants, preservatives, and pyrogen-free water.
14. The antitumor drug according to claim 9, characterized in that the tablets, sugar-coated tablets, capsules, pills and granules are prepared with coating films and shell materials.
Citation Information
Patent Citations
Beta-elemene monosubstituted amine derivatives, synthetic method and use thereof
CN101239915A
Beta-elemene halide and preparation method therefor
CN110683932A
Azo heterocycle beta-elemene piperazine alkyl derivative and its preparation and uses
CN1736991A
Beta-element nitrogenous derivative, and its preparing method and use
CN1850779A
Synthesis of negative beta-elemen, negative beta-elemenal, negative beta-elemenol, negative beta-fluoride-elemen and their analogues, intermediates, and pharmaceuticals, and their use
JP2008505893A
